Literature DB >> 29321176

Effects of Diabetes Medications Targeting the Incretin System on the Kidney.

Richard J MacIsaac1,2, Merlin C Thomas3.   

Abstract

Entities:  

Keywords:  Blood Glucose; Chronic; DPP4 protein; Diabetes Mellitus; Dipeptidyl Peptidase 4; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Homeostasis; Humans; Incretins; Peptide Hormones; Renal Insufficiency; Type 2; albuminuria; chronic kidney disease; diabetes; diabetic nephropathy; glomerular filtration rate; human; kidney; microalbuminuria; renal protection

Mesh：

Substances：

Year:  2018        PMID： 29321176      PMCID： PMC5967437          DOI： 10.2215/CJN.10380917

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  9 in total

1.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

Authors:  William B White; Christopher P Cannon; Simon R Heller; Steven E Nissen; Richard M Bergenstal; George L Bakris; Alfonso T Perez; Penny R Fleck; Cyrus R Mehta; Stuart Kupfer; Craig Wilson; William C Cushman; Faiez Zannad
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

2.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

3.  Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Rury R Holman; M Angelyn Bethel; Robert J Mentz; Vivian P Thompson; Yuliya Lokhnygina; John B Buse; Juliana C Chan; Jasmine Choi; Stephanie M Gustavson; Nayyar Iqbal; Aldo P Maggioni; Steven P Marso; Peter Öhman; Neha J Pagidipati; Neil Poulter; Ambady Ramachandran; Bernard Zinman; Adrian F Hernandez
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

4.  Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.

Authors:  Jan H Cornel; George L Bakris; Susanna R Stevens; Michael Alvarsson; Willem A Bax; Lee-Ming Chuang; Samuel S Engel; Renato D Lopes; Darren K McGuire; Axel Riefflin; Helena Wachslicht Rodbard; Isaac Sinay; Tsvetalina Tankova; Julio Wainstein; Eric D Peterson; Rury R Holman
Journal:  Diabetes Care       Date:  2016-10-14       Impact factor: 19.112

5.  Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.

Authors:  Ofri Mosenzon; Gil Leibowitz; Deepak L Bhatt; Avivit Cahn; Boaz Hirshberg; Cheryl Wei; KyungAh Im; Aliza Rozenberg; Ilan Yanuv; Christina Stahre; Kausik K Ray; Nayyar Iqbal; Eugene Braunwald; Benjamin M Scirica; Itamar Raz
Journal:  Diabetes Care       Date:  2016-10-17       Impact factor: 19.112

Review 6.  The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes.

Authors:  Merlin C Thomas
Journal:  Diabetes Metab       Date:  2017-04       Impact factor: 6.041

7.  Liraglutide and Renal Outcomes in Type 2 Diabetes.

Authors:  Johannes F E Mann; David D Ørsted; Kirstine Brown-Frandsen; Steven P Marso; Neil R Poulter; Søren Rasmussen; Karen Tornøe; Bernard Zinman; John B Buse
Journal:  N Engl J Med       Date:  2017-08-31       Impact factor: 91.245

8.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

Authors:  Marc A Pfeffer; Brian Claggett; Rafael Diaz; Kenneth Dickstein; Hertzel C Gerstein; Lars V Køber; Francesca C Lawson; Lin Ping; Xiaodan Wei; Eldrin F Lewis; Aldo P Maggioni; John J V McMurray; Jeffrey L Probstfield; Matthew C Riddle; Scott D Solomon; Jean-Claude Tardif
Journal:  N Engl J Med       Date:  2015-12-03       Impact factor: 91.245

9.  Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.

Authors:  Per-Henrik Groop; Mark E Cooper; Vlado Perkovic; Berthold Hocher; Keizo Kanasaki; Masakazu Haneda; Guntram Schernthaner; Kumar Sharma; Robert C Stanton; Robert Toto; Jessica Cescutti; Maud Gordat; Thomas Meinicke; Audrey Koitka-Weber; Sandra Thiemann; Maximilian von Eynatten
Journal:  Diabetes Obes Metab       Date:  2017-07-31       Impact factor: 6.577
  9 in total
  5 in total

Review 1.  Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).

Authors:  Raymond Vanholder; Steven Van Laecke; Griet Glorieux; Francis Verbeke; Esmeralda Castillo-Rodriguez; Alberto Ortiz
Journal:  Toxins (Basel)       Date:  2018-06-12       Impact factor: 4.546

2.  Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.

Authors:  Vlado Perkovic; Robert Toto; Mark E Cooper; Johannes F E Mann; Julio Rosenstock; Darren K McGuire; Steven E Kahn; Nikolaus Marx; John H Alexander; Bernard Zinman; Egon Pfarr; Sven Schnaidt; Thomas Meinicke; Maximillian von Eynatten; Jyothis T George; Odd Erik Johansen; Christoph Wanner
Journal:  Diabetes Care       Date:  2020-05-22       Impact factor: 19.112

Review 3.  Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease.

Authors:  Sebastian Niezen; Humberto Diaz Del Castillo; Lumen A Mendez Castaner; Alessia Fornoni
Journal:  Endocrinol Diabetes Metab       Date:  2019-05-17

4.  Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial.

Authors:  Christoph Wanner; Mark E Cooper; Odd Erik Johansen; Robert Toto; Julio Rosenstock; Darren K McGuire; Steven E Kahn; Egon Pfarr; Sven Schnaidt; Maximilian von Eynatten; Jyothis T George; Nicholas D Gollop; Nikolaus Marx; John H Alexander; Bernard Zinman; Vlado Perkovic
Journal:  Clin Kidney J       Date:  2021-01-17

Review 5.  Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials.

Authors:  David M Williams; Asif Nawaz; Marc Evans
Journal:  Diabetes Ther       Date:  2019-12-20       Impact factor: 2.945
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.